NuVasive, Inc. (NUVA - Free Report) will unveil its recent technologies in robotics that will revolutionize spine care at the North American Spine Society (“NASS”) Annual Meeting (from September 25-28, 2019) at McCormick Place in Chicago.
The company, focused on upgrading its spine surgery portfolio with minimally disruptive, procedurally integrated solutions, is a key player in this field. The company’s effort is expected to expand its offerings in the global robotic spine surgery space.
NuVasive’s Line of Technologies at NASS
As part of the Pulse platform, the company plans to unveil the Pulse Robotics application that will introduce automation. The application will also enable surgeons to optimize clinical decision making and deliver better patient outcomes.
Other products from NuVasive that are expected to be showcased include the X360 system. The product is a comprehensive approach to lateral single-position surgery, driven by the Pulse platform. The all-inclusive Advanced Materials Science implant portfolio, which now includes cervical offerings and a full portfolio for all TLIF procedures as well as Reline fixation system updates along with other procedural technologies, will also be displayed.
A Peek Into NuVasive’s Spine Portfolio
The company believes that its spine surgery portfolio, which is based on the Pulse platform, is the only system that assimilates several technologies in a single expandable platform designed for all spine procedures.
Per the management, the technologically advanced platform is of immense help to surgeons as well as patients. It reduces blood loss, hospital stays and operative morbidity, unlike open spine surgery.
This platform combines several technologies to reduce variability and improve workflow and the reproducibility of surgeries that incorporate neuromonitoring and surgical planning.
Per a report by Transparency Market Research, the global spine surgery robots market was valued at $75 million in 2018 and is expected to see a CAGR of 17.5% from 2018 to 2026. Some key factors that are driving the market are higher adoption of spine surgical robots and rise in the number of products receiving regulatory approval.
Given the current trend and future prospects, this move to showcase upgraded products is well-timed.
Of late, NuVasive has made certain developments with respect to its spine surgery procedures.
The company commercially launched the Modulus Cervical, a porous titanium interbody implant for cervical applications, in September. With this launch, the company expanded its Advanced Materials Science (AMS) portfolio to include Porous PEEK and porous titanium offerings for anterior cervical discectomy and fusion (ACDF) procedures, a common surgery to tackle cervical disc degeneration or spinal instability.
The company also commercially launched the ModulusTLIF-A, a porous titanium spine implant, in August this year. This has been designed for the transforaminal lumbar interbody fusion (TLIF) procedure.
The company’s shares have declined 6.9% in the past year, compared with the industry’s decline of 4.3%. However, the S&P 500 index inched up 1.1% during the same period.
Zacks Rank & Key Picks
Currently, NuVasive carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Valeritas Holdings, Inc (VLRX - Free Report) , GW Pharmaceuticals PLC (GWPH - Free Report) and Neurotrope, Inc (NTRP - Free Report) .
Valeritas, carrying a Zacks Rank #2 (Buy), has projected third-quarter 2019 earnings growth rate of 43.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GW Pharmaceuticals estimates third-quarter earnings growth rate to be 72.8%. It currently flaunts a Zacks Rank #1.
Neurotrope, with a Zacks Rank #2, has projected third-quarter earnings growth rate of 27.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>